PFM Health Sciences LP Invests $2.32 Million in Capricor Therapeutics Inc (NASDAQ:CAPR)

PFM Health Sciences LP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the third quarter, Holdings Channel reports. The institutional investor bought 152,779 shares of the biotechnology company’s stock, valued at approximately $2,324,000.

Other institutional investors also recently modified their holdings of the company. Main Street Financial Solutions LLC increased its stake in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares in the last quarter. SG Americas Securities LLC bought a new stake in Capricor Therapeutics in the 3rd quarter valued at about $133,000. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the 2nd quarter worth approximately $147,000. The Manufacturers Life Insurance Company acquired a new position in Capricor Therapeutics during the 3rd quarter worth approximately $161,000. Finally, BNP Paribas Financial Markets boosted its holdings in Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock worth $269,000 after acquiring an additional 15,872 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CAPR. Maxim Group boosted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. HC Wainwright restated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday, November 14th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Piper Sandler assumed coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 price objective for the company. Finally, Cantor Fitzgerald upped their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.50.

Insider Activity

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business’s stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.00% of the stock is currently owned by corporate insiders.

Capricor Therapeutics Trading Down 0.2 %

NASDAQ CAPR opened at $19.01 on Friday. The firm has a market capitalization of $864.38 million, a P/E ratio of -17.93 and a beta of 4.00. The business has a fifty day simple moving average of $18.03 and a 200 day simple moving average of $9.38. Capricor Therapeutics Inc has a 12 month low of $2.90 and a 12 month high of $23.40.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.